

[FDA Home](#)³ [Drug Databases](#)⁴ [Inactive Ingredient Search](#)

Inactive Ingredient Search for Approved Drug Products

[About this Database](#)⁵ [Back to Search Page](#)

Search Results for: "butylated"

INACTIVEINGREDIENT ⁶	ROUTE;DOSAGE FORM ⁷	CAS NUMBER ⁸	UNII ⁹	MAXIMUM POTENCY ¹⁰
BASIC BUTYLATED METHACRYLATE COPOLYMER	ORAL; TABLET, ORALLY DISINTEGRATING	24938167	905HNO1SIH	10MG
BUTYLATED HYDROXYANISOLE	INTRAMUSCULAR; INJECTION	25013165	REK4960K2U	0.03%
BUTYLATED HYDROXYANISOLE	IV(INFUSION); INJECTION	25013165	REK4960K2U	0.0003%
BUTYLATED HYDROXYANISOLE	IV(INFUSION); POWDER, FOR INJECTION SOLUTION	25013165	REK4960K2U	
BUTYLATED HYDROXYANISOLE	NASAL; SOLUTION	25013165	REK4960K2U	2%
BUTYLATED HYDROXYANISOLE	NASAL; SPRAY, METERED	25013165	REK4960K2U	0.0002%
BUTYLATED HYDROXYANISOLE	ORAL; CAPSULE	25013165	REK4960K2U	0.1MG
BUTYLATED HYDROXYANISOLE	ORAL; CAPSULE, SOFT GELATIN	25013165	REK4960K2U	1MG
BUTYLATED HYDROXYANISOLE	ORAL; CONCENTRATE	25013165	REK4960K2U	0.0075%
BUTYLATED HYDROXYANISOLE	ORAL; EMULSION	25013165	REK4960K2U	
BUTYLATED HYDROXYANISOLE	ORAL; GRANULE, FOR SUSPENSION	25013165	REK4960K2U	
BUTYLATED HYDROXYANISOLE	ORAL; SOLUTION	25013165	REK4960K2U	0.0189%
BUTYLATED HYDROXYANISOLE	ORAL; SUSPENSION	25013165	REK4960K2U	0.05%
BUTYLATED HYDROXYANISOLE	ORAL; TABLET	25013165	REK4960K2U	0.5MG
BUTYLATED HYDROXYANISOLE	ORAL; TABLET, FILM COATED	25013165	REK4960K2U	0.4MG
BUTYLATED HYDROXYANISOLE	ORAL; TABLET, ORALLY DISINTEGRATING	25013165	REK4960K2U	0.16MG
BUTYLATED HYDROXYANISOLE	RECTAL; SUPPOSITORY	25013165	REK4960K2U	0.213MG
BUTYLATED HYDROXYANISOLE	SUBLINGUAL; TABLET	25013165	REK4960K2U	0.5MG
BUTYLATED HYDROXYANISOLE	TOPICAL; EMULSION, CREAM	25013165	REK4960K2U	0.1%
BUTYLATED HYDROXYANISOLE	TOPICAL; GEL	25013165	REK4960K2U	0.05%
BUTYLATED HYDROXYANISOLE	TOPICAL; LOTION	25013165	REK4960K2U	
BUTYLATED HYDROXYANISOLE	TOPICAL; OINTMENT	25013165	REK4960K2U	0.005%
BUTYLATED HYDROXYANISOLE	TOPICAL; SOLUTION	25013165	REK4960K2U	
BUTYLATED HYDROXYANISOLE	VAGINAL; EMULSION, CREAM	25013165	REK4960K2U	0.125%
BUTYLATED HYDROXYANISOLE	VAGINAL; OINTMENT	25013165	REK4960K2U	0.02%
BUTYLATED HYDROXYANISOLE	VAGINAL; SUPPOSITORY	25013165	REK4960K2U	1MG
BUTYLATED	BUCCAL; GUM, CHEWING	128370	1P9D0Z171K	0.21MG

HYDROXYTOLUENE				
BUTYLATED HYDROXYTOLUENE	INTRAMUSCULAR; INJECTION	128370	1P9D0Z171K	0.03%
BUTYLATED HYDROXYTOLUENE	INTRAVENOUS; POWDER, FOR INJECTION SOLUTION, LYOPHILIZED	128370	1P9D0Z171K	0.0015%
BUTYLATED HYDROXYTOLUENE	INTRAVENOUS; SOLUTION, INJECTION	128370	1P9D0Z171K	0.002%
BUTYLATED HYDROXYTOLUENE	IV(INFUSION); INJECTION	128370	1P9D0Z171K	0.001%
BUTYLATED HYDROXYTOLUENE	IV(INFUSION); POWDER, FOR INJECTION SOLUTION	128370	1P9D0Z171K	
BUTYLATED HYDROXYTOLUENE	NASAL; SPRAY, METERED	128370	1P9D0Z171K	0.01%
BUTYLATED HYDROXYTOLUENE	ORAL; CAPSULE	128370	1P9D0Z171K	0.2MG
BUTYLATED HYDROXYTOLUENE	ORAL; CAPSULE, SOFT GELATIN	128370	1P9D0Z171K	0.25MG
BUTYLATED HYDROXYTOLUENE	ORAL; FILM, SOLUBLE	128370	1P9D0Z171K	0.06MG
BUTYLATED HYDROXYTOLUENE	ORAL; SOLUTION	128370	1P9D0Z171K	0.0189%
BUTYLATED HYDROXYTOLUENE	ORAL; SOLUTION, LIQUID, CONCENTRATE, ORAL	128370	1P9D0Z171K	0.01%
BUTYLATED HYDROXYTOLUENE	ORAL; TABLET	128370	1P9D0Z171K	0.4MG
BUTYLATED HYDROXYTOLUENE	ORAL; TABLET (IMMED./COMP. RELEASE), FILM COATED	128370	1P9D0Z171K	0.15MG
BUTYLATED HYDROXYTOLUENE	ORAL; TABLET, CONTROLLED RELEASE	128370	1P9D0Z171K	0.21MG
BUTYLATED HYDROXYTOLUENE	ORAL; TABLET, EXTENDED RELEASE	128370	1P9D0Z171K	0.11MG
BUTYLATED HYDROXYTOLUENE	ORAL; TABLET, FILM COATED	128370	1P9D0Z171K	0.36MG
BUTYLATED HYDROXYTOLUENE	ORAL; TABLET, FOR SUSPENSION	128370	1P9D0Z171K	0.1MG
BUTYLATED HYDROXYTOLUENE	ORAL; TABLET, SUSTAINED ACTION	128370	1P9D0Z171K	0.24MG
BUTYLATED HYDROXYTOLUENE	RECTAL; SUPPOSITORY	128370	1P9D0Z171K	0.213MG
BUTYLATED HYDROXYTOLUENE	TOPICAL; AEROSOL	128370	1P9D0Z171K	0.1%
BUTYLATED HYDROXYTOLUENE	TOPICAL; CREAM, AUGMENTED	128370	1P9D0Z171K	0.05%
BUTYLATED HYDROXYTOLUENE	TOPICAL; CREAM, EMULSION, SUSTAINED RELEASE	128370	1P9D0Z171K	0.1%
BUTYLATED HYDROXYTOLUENE	TOPICAL; EMULSION, AEROSOL FOAM	128370	1P9D0Z171K	0.1%
BUTYLATED HYDROXYTOLUENE	TOPICAL; EMULSION, CREAM	128370	1P9D0Z171K	0.1%
BUTYLATED HYDROXYTOLUENE	TOPICAL; GEL	128370	1P9D0Z171K	2%
BUTYLATED HYDROXYTOLUENE	TOPICAL; LOTION	128370	1P9D0Z171K	0.02%
BUTYLATED HYDROXYTOLUENE	TOPICAL; OINTMENT	128370	1P9D0Z171K	0.025%
BUTYLATED HYDROXYTOLUENE	TOPICAL; SHAMPOO	128370	1P9D0Z171K	0.1%
BUTYLATED HYDROXYTOLUENE	TOPICAL; SOLUTION	128370	1P9D0Z171K	0.088%
BUTYLATED HYDROXYTOLUENE	TOPICAL; SWAB	128370	1P9D0Z171K	

BUTYLATED HYDROXYTOLUENE	TRANSDERMAL; GEL	128370	1P9D0Z171K	0.05%
BUTYLATED HYDROXYTOLUENE	VAGINAL; EMULSION, CREAM	128370	1P9D0Z171K	0.05%
BUTYLATED HYDROXYTOLUENE	VAGINAL; SUPPOSITORY	128370	1P9D0Z171K	

Update Frequency: Quarterly

Data Through: September 16, 2013

Database Last Updated: October 24, 2013

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. <http://www.fda.gov/Drugs/InformationOnDrugs/ucm080123.htm>
6. <http://www.fda.gov/Drugs/InformationOnDrugs/ucm075230.htm>
7. <http://www.fda.gov/Drugs/InformationOnDrugs/ucm075230.htm>
8. <http://www.fda.gov/Drugs/InformationOnDrugs/ucm075230.htm>
9. <http://www.fda.gov/Drugs/InformationOnDrugs/ucm075230.htm>
10. <http://www.fda.gov/Drugs/InformationOnDrugs/ucm075230.htm>

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA No Fear Act](#) [Site Map](#) [Transparency](#) [Website Policies](#)

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)

[Email FDA](#)



[For Government For Press](#)

[Combination Products](#) [Advisory Committees](#) [Science & Research](#) [Regulatory Information](#) [Safety](#) [Emergency](#) [Preparedness](#) [International Programs](#) [News & Events](#) [Training and Continuing Education](#) [Inspections/Compliance](#) [State & Local Officials](#) [Consumers](#) [Industry](#) [Health Professionals](#) [FDA Archive](#)



U.S. Department of **Health & Human Services**

Links on this page:

[FDA Home](#)³ [Drug Databases](#)⁴ [Inactive Ingredient Search](#)

Inactive Ingredient Search for Approved Drug Products

[About this Database](#)⁵ [Back to Search Page](#)

Search Results for: "tocopherol"

INACTIVEINGREDIENT ⁶	ROUTE;DOSAGE FORM ⁷	CAS NUMBER ⁸	UNII ⁹	MAXIMUM POTENCY ¹⁰
.ALPHA.-TOCOPHEROL	INTRAVENOUS; INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSPENSION		H4N855PNZ1	0.064%
.ALPHA.-TOCOPHEROL	ORAL; CAPSULE		H4N855PNZ1	0.5MG
.ALPHA.-TOCOPHEROL	ORAL; CAPSULE, SOFT GELATIN		H4N855PNZ1	5MG
.ALPHA.-TOCOPHEROL	ORAL; TABLET		H4N855PNZ1	0.3MG
.ALPHA.-TOCOPHEROL	ORAL; TABLET, EXTENDED RELEASE		H4N855PNZ1	0.2MG
.ALPHA.-TOCOPHEROL	TOPICAL; OINTMENT		H4N855PNZ1	0.002%
.ALPHA.-TOCOPHEROL ACETATE, DL-	TOPICAL; EMULSION, AEROSOL FOAM	52225204	WR1WPI7EW8	0.002%
.ALPHA.-TOCOPHEROL ACETATE, DL-	TOPICAL; OINTMENT	52225204	WR1WPI7EW8	0.002%
.ALPHA.-TOCOPHEROL, DL-	INTRAVENOUS; SOLUTION, CONCENTRATE	10191410	7QWA1RIO01	0.075%
.ALPHA.-TOCOPHEROL, DL-	ORAL; CAPSULE, SOFT GELATIN	10191410	7QWA1RIO01	0.08MG
.ALPHA.-TOCOPHEROL, DL-	TOPICAL; OINTMENT	10191410	7QWA1RIO01	0.002%
TOCOPHEROL	ORAL; CAPSULE	1406662	R0ZB2556P8	
TOCOPHEROL	TOPICAL; OINTMENT	1406662	R0ZB2556P8	0.002%

Update Frequency: Quarterly
 Data Through: September 16, 2013
 Database Last Updated: October 24, 2013

Links on this page:

- <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>
- <http://www.addthis.com/bookmark.php>
- <http://www.fda.gov/default.htm>
- <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
- <http://www.fda.gov/Drugs/InformationOnDrugs/ucm080123.htm>
- <http://www.fda.gov/Drugs/InformationOnDrugs/ucm075230.htm>
- <http://www.fda.gov/Drugs/InformationOnDrugs/ucm075230.htm>
- <http://www.fda.gov/Drugs/InformationOnDrugs/ucm075230.htm>
- <http://www.fda.gov/Drugs/InformationOnDrugs/ucm075230.htm>
- <http://www.fda.gov/Drugs/InformationOnDrugs/ucm075230.htm>

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA No Fear Act](#) [Site Map](#) [Transparency](#) [Website Policies](#)

U.S. Food and Drug Administration
 10903 New Hampshire Avenue
 Silver Spring, MD 20993
 Ph. 1-888-INFO-FDA (1-888-463-6332)
[Email FDA](#)



[For Government For Press](#)

[Combination Products](#) [Advisory Committees](#) [Science & Research](#) [Regulatory Information](#) [Safety](#) [Emergency](#) [Preparedness](#) [International Programs](#) [News & Events](#)
[Training and Continuing Education](#) [Inspections/Compliance](#) [State & Local Officials](#) [Consumers](#) [Industry](#) [Health Professionals](#) [FDA Archive](#)

U.S. Department of Health & Human Services

Links on this page: